ArticleBritish journal of cancer2021

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.

Thomas Decaens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.